GPC Biotech To Resubmit Orplatna With Overall Survival Data

Company announces it will withdraw the NDA for satraplatin for prostate cancer based on outcome of advisory committee meeting.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet